(MENAFN- Newswire.com LLC) RESEARCH TRIANGLE PARK, N.C.,
June 12, 2019(Newswire.com) -
Alievio , a medical device company formerly known as Camras Vision, announced its name change today as part of a rebranding effort to further position the company as a leader in innovative glaucoma treatment solutions.
Ray Krauss, Chief Executive Officer at Alievio, said, 'It has long been our mission to help patients who suffer from this debilitating disease preserve what precious vision they still have and enjoy a higher quality of life.'
The name Alievio highlights the mission of the company, to alleviate and provide a sense of relief to those patients suffering from late-stage glaucoma, instilling a sense of hope and optimism of retaining their remaining vision through a new and innovative glaucoma treatment option.
The rebranding includes a newly designed website, logo and communication assets. Alievio's new logo is meant to express the high level of technology and science that is behind the design of the device, conveying the company's target to be at the forefront of innovation in the glaucoma treatment space. The website affords the reader a thorough background on general glaucoma education and outlines how Alievio's device meets a significant unmet need in lowering intraocular pressure (IOP), in comparison to current technologies and treatment options in the space.
As Alievio's device progresses towards commercialization, the company intends to generate awareness about glaucoma treatment for those late-stage patients who have failed to find relief and slow the progression of the disease with existing treatment options.
Contact Info
Name: Ray Krauss / CEO
Organization: Alievio, Inc.
Email:
Company URL:www.alievio.com
Address: 2 Davis Dr, Research Triangle, NC 27709
MENAFN1206201900704191ID1098635825
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.